Sage Therapeutics, Inc.

Sage Therapeutics appears to have finally secured a palatable exit for investors after facing R&D setbacks and cost cuts and rejecting an initial buyout offer from its Zurzuvae (zuranolone) commer

Biogen protected itself from tariffs on products imported from outside the US before there ever was a notion that US President Donald Trump would enact double-digit tariffs this year by virtue of wher

CEO Christopher Viehbacher has been straightforward about Biogen’s challenges since taking the helm in November 2022, and that did not change as the company reported its fourth-quarter and full-year 2

The US Food and Drug Administration maintained a high rate of complete response letter actions for novel agent applications in 2024, but recent history suggests that many of the 16 CRL recipients will